These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8767110)

  • 1. Synthesis of potent and orally active HIV-protease inhibitors.
    Capraro HG; Bold G; Fässler A; Cozens R; Klimkait T; Lazdins J; Mestan J; Poncioni B; Rösel JL; Stover D; Lang M
    Arch Pharm (Weinheim); 1996 Jun; 329(6):273-8. PubMed ID: 8767110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
    Melnick M; Reich SH; Lewis KK; Mitchell LJ; Nguyen D; Trippe AJ; Dawson H; Davies JF; Appelt K; Wu BW; Musick L; Gehlhaar DK; Webber S; Shetty B; Kosa M; Kahil D; Andrada D
    J Med Chem; 1996 Jul; 39(14):2795-811. PubMed ID: 8709110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
    Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
    Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
    Ghosh AK; Jadhav RD; Simpson H; Kovela S; Osswald H; Agniswamy J; Wang YF; Hattori SI; Weber IT; Mitsuya H
    Eur J Med Chem; 2018 Dec; 160():171-182. PubMed ID: 30340140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.
    Barrish JC; Gordon E; Alam M; Lin PF; Bisacchi GS; Chen P; Cheng PT; Fritz AW; Greytok JA; Hermsmeier MA
    J Med Chem; 1994 Jun; 37(12):1758-68. PubMed ID: 8021916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
    Ghosh AK
    J Med Chem; 2009 Apr; 52(8):2163-76. PubMed ID: 19323561
    [No Abstract]   [Full Text] [Related]  

  • 7. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.
    Bouzide A; Sauvé G; Yelle J
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1509-13. PubMed ID: 15713418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
    Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
    J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of a novel series of HIV-1 protease inhibitors.
    Takashiro E; Nakamura Y; Miyamoto S; Ozawa Y; Sugiyama A; Fujimoto K
    Bioorg Med Chem; 1999 Sep; 7(9):2105-14. PubMed ID: 10530961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, antiviral activity, and bioavailability studies of gamma-lactam derived HIV protease inhibitors.
    Hungate RW; Chen JL; Starbuck KE; Vacca JP; McDaniel SL; Levin RB; Dorsey BD; Guare JP; Holloway MK; Whitter W
    Bioorg Med Chem; 1994 Sep; 2(9):859-79. PubMed ID: 7712123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.
    Humber DC; Bamford MJ; Bethell RC; Cammack N; Cobley K; Evans DN; Gray NM; Hann MM; Orr DC; Saunders J
    J Med Chem; 1993 Oct; 36(21):3120-8. PubMed ID: 8230098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.
    Chiummiento L; Funicello M; Lupattelli P; Tramutola F; Berti F; Marino-Merlo F
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2948-50. PubMed ID: 22414613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
    Mak CC; Le VD; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem Lett; 2001 Jan; 11(2):219-22. PubMed ID: 11206463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.
    Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; McDonald E; Vasavanonda S; Wideburg N; Saldivar A; Robins T
    Biochem Biophys Res Commun; 1995 Jun; 211(1):159-65. PubMed ID: 7779082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
    Kiso Y
    Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
    [No Abstract]   [Full Text] [Related]  

  • 18. Design and synthesis of novel conformationally restricted HIV protease inhibitors.
    Salituro FG; Baker CT; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Porter MD; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3637-42. PubMed ID: 9934485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
    Lu Z; Raghavan S; Bohn J; Charest M; Stahlhut MW; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2003 May; 13(10):1821-4. PubMed ID: 12729673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.